www.fdanews.com/articles/71958-seattle-genetics-launches-manufacturing-campaign-with-albany-molecular
Seattle Genetics Launches Manufacturing Campaign With Albany Molecular
May 5, 2005
Seattle Genetics announced that it has entered into an agreement with Albany Molecular Research for cGMP manufacturing of the proprietary drug-linker system employed in its SGN-35 product candidate. SGN-35 is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody stably linked to a highly potent auristatin derivative using Seattle Genetics' second generation ADC technology. The company announced earlier it was issued a U.S. patent covering the cell-killing drug component used in SGN-35.